Tag Archives | mass spec

Rayno DX and Tools Mid Year Review and AACC Update: ABAX, ILMN, HOLX, TMO.. Update-2

Update -2 Aug. 1 Draft Guidance on LDTs Coming from FDA in 60 Days: Tests Must Be Validated More regulation coming means greater development costs and potential time delays for clinical tests in development and currently marketed as LDTs . Presumably LDT tests will be allowed to remain on the market. Potential intermediate term impact […]

Continue Reading 0

Rodman&Renshaw Notes Part 2: Sequenom (SQNM)

Sequenom (SQNM) $7, Market Cap $529M, 76M Sh. Outstanding Sequenom presented a financial update and their plans for their T21 trisomy 21 noninvasive pre-natal test for fetal gene and chromosomal abnormalities. The Company plans to launch a CLIA LDT (lab developed test) by Q4 2011 and submit a PMA by late 2012. The T21 test […]

Continue Reading 0

Sequenom (SQNM) Catching Bids at $5.75

Sequenom is finding price support today at $5.75, volume of 4.6M at 1p, after a severe three  day downdraft triggered by their earnings release. Net loss for Q4 was $18.4M on Revenues of $10.8M. Cash position is $42M. Some pundits didn’t like the inability of the Company to give a detailed financial outlook but that […]

Continue Reading 0